All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
triphenylethylene
the core chemical structure of a number of related anti-estrogen compounds. The triphenylethylene antiestrogens, which include idoxifene, toremifene…Â
(More)
Topic mentions per year
Topic mentions per year
1947-2016
0
5
10
15
1947
2015
Related topics
Related topics
2 relations
Broader (2)
Estrogen Antagonists
Stilbenes
Related mentions per year
Related mentions per year
1939-2018
1940
1960
1980
2000
2020
triphenylethylene
Stilbenes
Estrogen Antagonists
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
A new triphenylethylene compound, Fc-1157a
Lauri Kangas
,
A. Nieminen
,
+6 authors
Reijo Toivola
Cancer Chemotherapy and Pharmacology
2004
The antitumor effects of a new antiestrogen, Fc-1157a1 have been studied in vitro and in vivo. In vitro the effect of Fc-1157a…Â
(More)
Is this relevant?
2000
2000
Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Qi Qu
,
H Zheng
,
+8 authors
Pirkko L. Härkönen
Endocrinology
2000
FC1271a is a novel triphenylethylene compound with a tissue-selective profile of estrogen agonistic and weak antagonistic effects…Â
(More)
Is this relevant?
Highly Cited
1994
Highly Cited
1994
Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions.
Moshe Tzukerman
,
A C Esty
,
+5 authors
D P Mcdonnell
Molecular endocrinology
1994
We have used a series of human estrogen receptor (ER) mutants to evaluate the cell- and promoter-specific transcriptional…Â
(More)
Is this relevant?
Highly Cited
1993
Highly Cited
1993
The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat.
G. Milville Williams
,
Michael J. Iatropoulos
,
Maja Djordjević
,
O P Kaltenberg
Carcinogenesis
1993
Tamoxifen (TAM) is used in the treatment of breast cancer and is being given to healthy women to inhibit breast cancer. The…Â
(More)
Is this relevant?
1992
1992
Desmoid tumours treated with triphenylethylenes.
Malcolm Brooks
,
Steve R Ebbs
,
Anthony A. Colletta
,
M. Baum
European journal of cancer
1992
Desmoids are uncommon mesenchymal tumours that occur at single or multiple anatomical sites, occasionally in association with…Â
(More)
Is this relevant?
1988
1988
Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme.
C A O'brian
,
Nick Ward
,
Beverly Anderson
Journal of the National Cancer Institute
1988
The tumor promoter receptor protein kinase C (PKC) has been implicated as a key enzyme in cellular growth regulation. It is…Â
(More)
Is this relevant?
1987
1987
Triphenylethylene antiestrogen binding sites (TABS) specificity.
J. H. Clark
,
William Mitchell
,
S C Guthrie
Journal of steroid biochemistry
1987
The relative binding affinities (RBA) of various compounds for the triphenylethylene antiestrogen binding sites (TABS) were…Â
(More)
Is this relevant?
1986
1986
A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.
Laura C. Kangas
,
A. Nieminen
,
+6 authors
Ryan Toivola
Cancer chemotherapy and pharmacology
1986
The antitumor effects of a new antiestrogen, Fc-1157a have been studied in vitro and in vivo. In vitro the effect of Fc-1157a was…Â
(More)
Is this relevant?
1986
1986
Triphenylethylenes: a new class of protein kinase C inhibitors.
C A O'brian
,
Rob M. J. Liskamp
,
Davidson Solomon
,
I. B. Weinstein
Journal of the National Cancer Institute
1986
The Ca2+- and phospholipid-dependent phosphotransferase activity of protein kinase C was inhibited by the triphenylethylene…Â
(More)
Is this relevant?
1986
1986
Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells.
Alberto Gulino
,
G. Barrera
,
+5 authors
Luisa Frati
Cancer research
1986
The triphenylethylene antiestrogen tamoxifen has been shown previously to inhibit both calmodulin and protein kinase C activities…Â
(More)
Is this relevant?